Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of intranasal COVID-19 vaccine BBV154 in healthy volunteers
NCT04751682Phase 1Completed
- Sponsor
- Bharat Biotech
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iNCOVACC in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Bharat Biotech. Primary endpoints: Incidence of immediate adverse events, Incidence of solicited local and systemic adverse events and 2 more. Started Mar 2021; status: completed.
02
Drugs
iNCOVACC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04751682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04751682.